Tokyo, March 16, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that OSI Pharmaceuticals, Inc. (a subsidiary of Astellas), Genentech, Inc. (a member of the Roche Group - SIX: RO, ROG; OTCQX: RHHBY), and Pfizer Inc. (NYSE:PFE) have reached an agreement with Teva Pharmaceuticals USA, Inc. (“Teva”) to settle the pending U.S. litigation filed March 19, 2009 against Teva with regard to US Patent Nos. 6,900,221, RE 41,065 and 7,087,613 for Tarceva® (erlotinib hydrochloride) tablets, through which the case against Teva will be terminated by a Consent Order of Dismissal. The terms of the settlement are not disclosed.



Contact the Media Relations team
Communications & Investor Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)